| 01/18 | Canaccord Genuity Assumes Coverage on Ultragenyx Pharmaceutical With Buy Rating, $90 Pr.. | MT |
| 01/10 | Transcript : Ultragenyx Pharmaceutical Inc. Presents at 41st Annual J.P. Morg.. | CI |
| 01/09 | Ultragenyx reports preliminary 2022 revenue guidance for 2023 revenue and cash usage pi.. | AQ |
| 01/06 | Ultragenyx Pharmaceutical Reports Preliminary 2022 Revenue, Issues 2023 Guidance | MT |
| 01/06 | Ultragenyx Pharmaceutical Inc. : Results of Operations and Financial Condition, Regulation.. | AQ |
| 01/06 | Ultragenyx Reports Preliminary 2022 Revenue; Guidance for 2023 Revenue and Cash Usage; .. | GL |
| 01/06 | Ultragenyx Reports Preliminary 2022 Revenue; Guidance for 2023 Revenue and Cash Usage; .. | AQ |
| 01/06 | Ultragenyx Pharmaceutical Inc. Provides Revenue Guidance for the Year 2022 and 2023 | CI |
| 01/04 | Ultragenyx to Present at the 41st Annual J.P. Morgan Healthcare Conference | GL |
| 2022 | HC Wainwright Assumes Ultragenyx With Buy Rating, $82 Price Target | MT |
| 2022 | Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | GL |
| 2022 | Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | AQ |
| 2022 | Transcript : Ultragenyx Pharmaceutical Inc. Presents at Piper Sandler 34th An.. | CI |
| 2022 | Ultragenyx to Present at Piper Sandler Healthcare Conference | GL |
| 2022 | Ultragenyx to Present at Piper Sandler Healthcare Conference | GL |
| 2022 | Ultragenyx reports inducement grant under nasdaq listing rule 5635(4) | AQ |
| 2022 | Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | GL |
| 2022 | Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | AQ |
| 2022 | Transcript : Ultragenyx Pharmaceutical Inc. Presents at 13th Annual Jefferies.. | CI |
| 2022 | Transcript : Ultragenyx Pharmaceutical Inc. Presents at Stifel 2022 Healthcar.. | CI |
| 2022 | Ultragenyx Pharmaceutical Chief Financial Officer Mardi Dier to Depart for Private Biop.. | MT |
| 2022 | Ultragenyx Pharmaceutical Inc. : Change in Directors or Principal Officers (form 8-K) | AQ |
| 2022 | Ultragenyx Announces Departure of Chief Financial Officer | GL |
| 2022 | Ultragenyx Pharmaceutical Inc. Announces Departure of Mardi Dier, Executive Vice Presid.. | CI |
| 2022 | Ultragenyx Pharmaceutical Inc. Announces Departure of Mardi Dier, Chief Financial Offic.. | CI |
| 2022 | Ultragenyx to Present at Upcoming Healthcare Conferences | GL |
| 2022 | Ultragenyx to Present at Upcoming Healthcare Conferences | AQ |
| 2022 | Credit Suisse Adjusts Ultragenyx Pharmaceutical's Price Target to $96 From $105, Keeps .. | MT |
| 2022 | Baird Upgrades Ultragenyx Pharmaceutical to Outperform From Neutral, Adjusts Price Targ.. | MT |
| 2022 | Wedbush Lowers Ultragenyx Pharmaceutical's PT to $49 From $51, Says Waiting for Additio.. | MT |
| 2022 | ULTRAGENYX PHARMACEUTICAL INC. Management's Discussion and Analysis of Financial Condi.. | AQ |
| 2022 | Transcript : Ultragenyx Pharmaceutical Inc., Q3 2022 Earnings Call, Nov 02, 2.. | CI |
| 2022 | Ultragenyx : Q3 Earnings Snapshot | AQ |
| 2022 | Earnings Flash (RARE) ULTRAGENYX PHARMACEUTICAL Reports Q3 Revenue $90.7M | MT |
| 2022 | Ultragenyx Reports Third Quarter 2022 Financial Results and Corporate Update | GL |
| 2022 | Ultragenyx Reports Third Quarter 2022 Financial Results and Corporate Update | AQ |
| 2022 | Ultragenyx Pharmaceutical Inc. Reports Earnings Results for the Third Quarter and Nine .. | CI |
| 2022 | Ultragenyx Pharmaceutical Inc. Provides Revenue Guidance for 2022 | CI |
| 2022 | Ultragenyx Pharmaceutical Inc. : Submission of Matters to a Vote of Security Holders (form.. | AQ |
| 2022 | Ultragenyx to Host Conference Call for Third Quarter 2022 Financial Results and Corpora.. | GL |
| 2022 | Insider Sell: Ultragenyx Pharmaceutical | MT |
| 2022 | Wedbush Cuts Price Target on Ultragenyx Pharmaceutical to $51 From $68, Maintains Neutr.. | MT |
| 2022 | Guggenheim Upgrades Ultragenyx Pharmaceutical to Buy From Neutral; Price Target is $50 | MT |
| 2022 | Ultragenyx reports inducement grant under nasdaq listing rule 5635(4) | AQ |
| 2022 | Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | GL |
| 2022 | Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | AQ |
| 2022 | Ultragenyx Pharmaceutical Inc. : Change in Directors or Principal Officers (form 8-K) | AQ |
| 2022 | Ultragenyx and Mereo BioPharma to Present Setrusumab Data Update at ASBMR | AQ |
| 2022 | Ultragenyx and Mereo BioPharma to Present Setrusumab Data Update at ASBMR | GL |
| 2022 | Ultragenyx and Mereo BioPharma to Present Setrusumab Data Update at ASBMR | GL |
| 2022 | Transcript : Ultragenyx Pharmaceutical Inc. Presents at Citi's 17th Annual Bi.. | CI |
| 2022 | Ultragenyx to Participate at Citi BioPharma Conference | GL |
| 2022 | Ultragenyx to Participate at Citi BioPharma Conference | AQ |
| 2022 | Goldman Sachs Adjusts Price Target on Ultragenyx Pharmaceutical to $74 From $72, Reiter.. | MT |
| 2022 | Ultragenyx reports inducement grant under nasdaq listing rule 5635(4) | AQ |
| 2022 | Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | GL |
| 2022 | Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | AQ |
| 2022 | Ultragenyx reports inducement grant under nasdaq listing rule 5635(4) | AQ |
| 2022 | Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | GL |
| 2022 | Citigroup Adjusts Price Target on Ultragenyx Pharmaceutical to $142 From $146, Reiterat.. | MT |
| 2022 | Evercore ISI Downgrades Ultragenyx Pharmaceutical to In-Line From Outperform, Adjusts P.. | MT |
| 2022 | Wedbush Adjusts Price Target on Ultragenyx Pharmaceutical to $68 From $70, Maintains Ne.. | MT |
| 2022 | Ultragenyx Pharmaceutical : Quarterly Report for Quarter Ending June 30, 2022 (Form 10-Q) | PU |
| 2022 | Piper Sandler Adjusts Price Target on Ultragenyx Pharmaceutical to $130 From $135, Keep.. | MT |
| 2022 | ULTRAGENYX PHARMACEUTICAL INC. Management's Discussion and Analysis of Financial Condi.. | AQ |
| 2022 | Transcript : Ultragenyx Pharmaceutical Inc., Q2 2022 Earnings Call, Jul 28, 2.. | CI |
| 2022 | Ultragenyx Pharmaceutical : Reports Second Quarter 2022 Financial Results and Corporate Up.. | PU |
| 2022 | Ultragenyx Pharmaceutical Posts Wider Q2 Loss, Higher Revenue | MT |
| 2022 | Ultragenyx : Q2 Earnings Snapshot | AQ |
| 2022 | Ultragenyx Reports Second Quarter 2022 Financial Results and Corporate Update | GL |
| 2022 | Earnings Flash (RARE) ULTRAGENYX PHARMACEUTICAL Posts Q2 Revenue $89.3M | MT |
| 2022 | Ultragenyx Reports Second Quarter 2022 Financial Results and Corporate Update | GL |
| 2022 | Ultragenyx Pharmaceutical Inc. Provides Revenue Guidance for Full Year 2022 | CI |
| 2022 | Ultragenyx Pharmaceutical Inc. Reports Earnings Results for the Second Quarter and Six .. | CI |
| 2022 | Ultragenyx to Host Conference Call for Second Quarter 2022 Financial Results and Corpor.. | GL |
Google
Twitter
Facebook
Apple
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
Report
